Nutriband Inc. Completes Acquisition of 4P Therapeutics Inc.

Nutriband Inc announced the formal completion of the acquisition of Atlanta-based 4P Therapeutics Inc. Pursuant to the previously announced acquisition agreement, on Aug 1, 2018, Nutriband completed the acquisition of 4P Therapeutics for 250,000 shares of Nutriband’s common stock and cash of $400,000.

Gareth Sheridan, Chief Executive Officer of Nutriband, said, “4P Therapeutics is focused on the research and development of transdermal and novel drug delivery technologies and therapeutics.  As a result of the acquisition, we are acquiring 4P’s transdermal prescription pipeline in development, which consists of products to treat opioid abuse /misuse, diabetes, nausea, Infertility, Blood Pressure, Parkinson’s disease, and pain relief, which are in various stages of development.”